Ertugliflozin: a novel anti-diabetic drug

Sharma, Vikrant; Sharma, S. C.; Jaiswal, Sanjay; Ghanghas, Ravi R.; Bodepalli, Durgaprasad; Sharma, Ashok

doi:10.18203/2319-2003.ijbcp20184607

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Take precautions to avoid mosquito bites. The only way to avoid the spread of this disease is to protect yourself from mosquito bites [40,41]. Furthermore, the likelihood of severity varies from person to person according to their physical state and health history.…”

Section: Preventionmentioning

confidence: 99%

A Systematic Review on Malaria Disease and Its Treatments Focus on Artemether Drug

PHALAK,

BODKE,

BODKE

et al. 2024

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Malaria is one of the infectious illnesses of the highest scientific significance and importance to international health organizations. Plasmodium falciparum, the parasite responsible for a highly severe form of the disease in Africa, has traditionally received the most attention. However, in the last two decades, the Plasmodium vivax parasite, which is linked to a large number of cases in Latin America, the Middle East, South and Southeast Asia, the Horn of Africa, and Oceania, has sparked enormous interest, owing to published evidence that it can cause severe malaria, among other things. Malaria is a worldwide public health problem, with a saw 247 million cases recorded in 2021. African countries accounted for approximately 94% of all reported cases. So far, over 200 distinct varieties of protozoa have been discovered and identified, with at least 13 of them being pathogenic to humans. The malaria parasite's life cycle is a complex process involving a mosquito with the species Anopheles and a vertebrate host. Artemether is a lipid-soluble artemisinin derivative. It is available in both oral and intramuscular forms. It is also available as a fixed-dose formulation with lumefantrine. Artemether-lumefantrine is one of the ACTs authorized by the WHO and is being used by the majority of countries transitioning from less effective medications to ACTs. However, the emergence of antimalarial medication resistance poses a significant challenge to malaria control. It works by killing the pathogenic organisms responsible for malaria. It is known as an antimalarial medication, and it is more effective than quinine therapies.

show abstract

Section: Preventionmentioning

confidence: 99%

A Systematic Review on Malaria Disease and Its Treatments Focus on Artemether Drug

PHALAK,

BODKE,

BODKE

et al. 2024

Int J Curr Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Ertugliflozin developed to improve glycemic control in adults with T2D, met the primary outcomes in 2 years long Phase 3 trials, VERTIS SU (eValuation of ERTugliflozin effIcacy and Safety) and VERTIS SITA2 [21]. Ertugliflozin is the fourth SGLT2-is to be approved in the US and newest agent among SGLT2-i, having received FDA approval in December 2017 [50][51][52][53][54]. Ertugliflozin is recommended as an adjunct to diet and exercise for glycemic control in adults (≥18 years of age) with T2D.…”

Section: New Sglt2-imentioning

confidence: 99%

Sodium-Glucose Linked Cotransporter 2 Inhibitor: A New Horizon in the Treatment of Type-2 Diabetes

Bisht¹

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes (T2D) mellitus. The various therapeutic classes of antidiabetic drugs presently existing in the market are not sufficiently effective in maintaining long-term glycemic control in most of the diabetic patients, even when used in combination. The undesirable adverse effects of these drugs, such as hypoglycemia, weight gain, and hepatic and renal toxicity, have escalated the demand for the discovery of new and safer antidiabetic drugs. The progressive nature of T2D requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) are the new class of antidiabetic medications that are approved (2013) by the Food and Drug Administration recently for treating diabetes. These inhibitors block the SGLT2 protein involved in glucose reabsorption from the proximal renal tubule resulting in escalated glucose excretion and lower blood glucose levels. These inhibitors exhibit favorable effects beyond glucose control, such as consistent body weight, blood pressure, and serum uric acid reductions. This review highlighted the brief updates of SGLT2-i, their benefits, and adverse effects.

show abstract

“…Ertugliflozin is a recent oral SGLT2 inhibitor that gets FDA approval as an antidiabetic drug. It prevents reabsorption of urine glucose and shows better control of body weight and blood pressure [138]. Ertugliflozin reduces cardiovascular risk due to a fair decline in blood pressure and body weight.…”

Section: Sodium-glucose Co-transporter-2 (Sglt2) Inhibitorsmentioning

confidence: 99%

Systematic Review on Medicaments Used in Management of Diabetes Mellitus

Jamwal¹

2020

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Diabetes has a global prevalence in developed countries and rapidly flexing its roots in middle-and low-income countries. According to the World Health Organization, it is a major cause of kidney collapse, heart problems, and lower limb amputation. Diabetes mellitus is a metabolic disorder showing an uncontrolled increase in blood glucose levels. To date, no permanent cure has been developed for the complete restoration of impaired glucose haemostasis. With the use of therapeutic agents and nontherapeutic agents, glucose levels can be kept in control for a very long time. The foremost goal of all current ongoing treatments is to control high blood glucose levels, reduction in elevated lipid levels, and delay in the progression of diabetes-related complications. Various therapeutics agents are developed in recent decades, which shown very promising results in the management of diabetes mellitus. These agents prescribed after reviewing the clinical symptoms and situation of an individual patient. This review compiles noteworthy information related to clinically approved medicaments for diabetes mellitus. Review emphasis on categorization, mechanism of action, noted adverse effects along with the physiological responses of used medicines to treat diabetes mellitus.

show abstract

Ertugliflozin: a novel anti-diabetic drug

Cited by 3 publications

References 7 publications

A Systematic Review on Malaria Disease and Its Treatments Focus on Artemether Drug

A Systematic Review on Malaria Disease and Its Treatments Focus on Artemether Drug

Sodium-Glucose Linked Cotransporter 2 Inhibitor: A New Horizon in the Treatment of Type-2 Diabetes

Systematic Review on Medicaments Used in Management of Diabetes Mellitus

Contact Info

Product

Resources

About